A5044524314- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Pregnancy and Medication Impact
- Colorectal Cancer Screening and Detection
- Acute Lymphoblastic Leukemia research
- Celiac Disease Research and Management
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Helicobacter pylori-related gastroenterology studies
- Diverticular Disease and Complications
- Gastroesophageal reflux and treatments
- Gastrointestinal motility and disorders
- Gastric Cancer Management and Outcomes
- Esophageal and GI Pathology
- Liver Diseases and Immunity
- Gastrointestinal disorders and treatments
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders Research
- Genetic factors in colorectal cancer
- Liver Disease Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Mycobacterium research and diagnosis
- Health Systems, Economic Evaluations, Quality of Life
- Gastrointestinal Bleeding Diagnosis and Treatment
University of Pennsylvania
2016-2025
Hospital of the University of Pennsylvania
2011-2021
University of Pennsylvania Health System
1999-2020
Specifica (United States)
2017
University Medical Center Utrecht
2016
University Hospital of Geneva
2015
Philadelphia VA Medical Center
2014
Pennsylvania Hospital
2009-2013
Albert Einstein College of Medicine
2010
Montefiore Medical Center
2010
The Mayo score and a noninvasive 9-point partial are used as outcome measures for clinical trials assessing therapy ulcerative colitis (UC). There limited data what defines clinically relevant change in these indices. We sought to assess constitutes meaningful indices using from recently completed placebo-controlled trial.In all, 105 patients were enrolled 12-week randomized, trial rosiglitazone treatment of mild moderate UC. compared the score, 6-point composed just stool frequency bleeding...
Infliximab is approved for the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). We report first large series pregnancy outcomes in women with RA CD exposed to infliximab.The infliximab safety database was queried all reports pregnancy. Data were extracted regarding indication infliximab, timing relative conception, course, outcome. The proportion live births, miscarriages, therapeutic terminations directly before or during confirmed compared those expected general U.S....
ABSTRACT Background Obesity has been linked to a more severe phenotype in patients with ulcerative colitis (UC). Aim To evaluate the impact of obesity on outcomes advanced therapies UC. Methods We conducted retrospective cohort study utilising TriNetX database comparing composite score corticosteroid use, change therapy or colectomy within two years between cohorts UC—those (BMI ≥ 30 kg/m 2 ) and those without 18.5–24.9). The risk assessment was stratified specific therapies, including...
Pyoderma gangrenosum is an immune-mediated inflammatory condition characterized by ulcerative skin lesions affecting 1-2% of patients with bowel disease (IBD). Treatment includes wound care, antibiotics, corticosteroids, and immunomodulators. However, response to therapy varies, many pyoderma have that refractory these agents. The aim this study was assess the medically infliximab.This a multicenter retrospective IBD treated infliximab. Data collected included following: baseline...
Tumor necrosis factor-alpha (TNF-alpha) is an important cytokine involved in the pathogenesis of inflammatory bowel disease. The monoclonal antibody to TNF-alpha, infliximab, effective treating Crohn's Preclinical studies suggest importance TNF-alpha ulcerative colitis (UC). We report effectiveness infliximab for UC and examine factors predictive response medication.Data from all patients receiving at four institutions were analyzed. Disease activity was determined by Activity Index.A total...